Meta-analysis of valve-related complications (bioprosthetic valve as reference)
| Outcome | No. of studies | No. of patients | RR or IRR* (95% CI) | p value | I2, % | Quality of evidence |
|---|---|---|---|---|---|---|
| Endocarditis | 12 | 1318 | 1.59 (0.91–2.79) | 0.11 | 0 | Very low |
| Myocardial infarction | 4 | 848 | 3.08 (1.14–8.30) | 0.02 | 0 | Very low |
| Valve thrombosis | 3 | 408 | 2.87 (0.34–24.52) | 0.33 | 23 | Very low |
| Systemic thromboembolism | 8 | 1067 | 2.20 (1.15–4.22) | 0.01 | 10 | Very low |
| Valve deterioration | 13 | 1385 | 0.60 (0.23–1.54) | 0.28 | 0 | Very low |
| Composite of valve-related complications | 13 | 1385 | 1.44 (0.71–2.91) | 0.32 | 24 | Very low |
CI = confidence interval; IRR = incident rate ratio; RR = relative risk.
↵* Relative risk is the effect estimate for outcomes of valve deterioration and the composite of valve-related complications. All other outcomes use incidental rate ratios as the effect estimate.